AltMountain

Spruce Street Capital LP

New York, NY · CRD 333213
Hedge fund manager

Spruce Street Capital LP is an SEC-registered investment adviser based in New York, NY that reports managing 3 hedge funds on Form ADV. It reports $555.9 million in regulatory assets under management. Its private funds, of all types, hold $900.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +62.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +62.5% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$555.9 millionForm ADV Item 5.F
Gross assets of private funds
$900.9 millionAll private fund types, Form ADV
Hedge funds managed
33 private funds in total
Employees
4Form ADV Item 5.A
Registration
SEC-registered adviserCRD 333213
Latest Form ADV
03/02/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+62.5%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+62.5%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$509.7 million30 positions, 2026-06-30
$95$129$162Q1 2026Q2 202613F est. $162S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+20.3%+14.8%
Q1 2026+35.1%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 39 share positions ($628,983,538) reported by Spruce Street Capital LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Kiniksa Pharmaceuticals Intl10.89%
  • LB Pharmaceuticals Inc8.56%
  • Relay Therapeutics Inc8.56%
  • Alto Neuroscience Inc6.80%
  • Alkermes PLC6.11%
  • Entera Bio LTD5.19%
  • Dianthus Therapeutics Inc4.97%
  • Savara Inc4.42%
  • Zai Lab LTD4.36%
  • Relmada Therapeutics Inc4.14%
StockValue% of 13F portfolioSharesShares vs prior quarter
Kiniksa Pharmaceuticals Intl$68,497,20310.89%918,070Unchanged
LB Pharmaceuticals Inc$53,863,4568.56%1,404,779+2.08%
Relay Therapeutics Inc$53,863,4568.56%2,984,125Unchanged
Alto Neuroscience Inc$42,802,5266.80%1,676,558+23.91%
Alkermes PLC$38,432,0456.11%948,471+74.39%
Entera Bio LTD$32,631,1545.19%11,213,455New
Dianthus Therapeutics Inc$31,241,5494.97%354,816Unchanged
Savara Inc$27,770,8164.42%5,381,941+55.88%
Zai Lab LTD$27,450,4424.36%1,042,158+273.39%
Relmada Therapeutics Inc$26,058,9604.14%6,912,191+8.15%
Vaxcyte Inc$17,414,0742.77%306,047Unchanged
Obsidian Therapeutics Inc$17,161,7172.73%1,249,943New
Enliven Therapeutics Inc$15,081,6352.40%329,006Unchanged
Enanta Pharmaceuticals Inc$14,349,4752.28%1,088,731Unchanged
Surrozen Inc$13,903,0472.21%432,040Unchanged
Sagimet Biosciences Inc$13,832,0002.20%1,400,000New
Yarrow Bioscience Inc$13,678,2432.17%607,382New
Inflarx NV$10,955,1061.74%6,086,170+13.71%
Korsana Biosciences Inc$10,304,1101.64%338,951New
Perspective Therapeutics Inc$10,158,3101.62%3,693,931Unchanged
An2 Therapeutics Inc$9,320,6991.48%1,752,011+5.47%
Inhibikase Therapeutics Inc$7,360,1941.17%3,581,603Unchanged
Sab Biotherapeutics Inc$6,969,2511.11%2,198,502Unchanged
Century Therapeutics Inc$6,940,9821.10%4,059,054Unchanged
Erasca Inc$6,194,4800.98%422,543Unchanged
Achieve Life Science Inc$5,959,3930.95%736,637Unchanged
Minerva Neurosciences Inc$5,545,9250.88%1,655,500Unchanged
Research Alliance Corp III$5,415,0000.86%500,000Unchanged
Research Alliance Corp IV$5,400,0000.86%450,000New
Helix Acquisition Corp III$5,310,0000.84%500,000Unchanged
Attovia Therapeutics Inc$3,912,9760.62%228,295New
Alector Inc$3,886,9760.62%2,101,068Unchanged
Tcgx Acquisition Corp$3,753,0000.60%300,000New
Lexeo Therapeutics Inc$3,138,6440.50%928,593Unchanged
Alumis Inc$2,901,1220.46%392,574Unchanged
Corvus Pharmaceuticals Inc$2,667,8590.42%231,585Unchanged
Jatt II Acquisition Corp$1,799,2000.29%160,000Unchanged
Jatt III Acquisition Corp$1,653,0000.26%150,000New
Leonabio Inc$1,405,5130.22%393,701Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 9 new positions, 0 sold out, 8 increased, 0 reduced and 22 unchanged.

Number of positions (a count, not dollars)

  • New positions9
  • Increased8
  • Unchanged22
  • Reduced0
  • Sold out0

New positions

StockValueShares
Entera Bio LTD$32,631,15411,213,455
Obsidian Therapeutics Inc$17,161,7171,249,943
Sagimet Biosciences Inc$13,832,0001,400,000
Yarrow Bioscience Inc$13,678,243607,382
Korsana Biosciences Inc$10,304,110338,951
Research Alliance Corp IV$5,400,000450,000
Attovia Therapeutics Inc$3,912,976228,295
Tcgx Acquisition Corp$3,753,000300,000
Jatt III Acquisition Corp$1,653,000150,000

Largest increases

StockChange in sharesChangeValue nowShares now
Zai Lab LTD+763,048+273.39%$27,450,4421,042,158
Alkermes PLC+404,595+74.39%$38,432,045948,471
Savara Inc+1,929,365+55.88%$27,770,8165,381,941
Alto Neuroscience Inc+323,511+23.91%$42,802,5261,676,558
Relmada Therapeutics Inc+520,863+8.15%$26,058,9606,912,191
Inflarx NV+733,972+13.71%$10,955,1066,086,170
LB Pharmaceuticals Inc+28,620+2.08%$53,863,4561,404,779
An2 Therapeutics Inc+90,938+5.47%$9,320,6991,752,011

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Yarrow Bioscience, Inc.13G6.4%607,382Nov 13, 2026SEC.gov ↗
Research Alliance Corp IV13G5.8%450,000Nov 13, 2026SEC.gov ↗
Entera Bio Ltd.13G6.4%11,213,455Nov 13, 2026SEC.gov ↗
LeonaBio, Inc.13G4.2%393,700Nov 13, 2026SEC.gov ↗
Research Alliance Corp III13G6.4%500,000Aug 13, 2026SEC.gov ↗
Relmada Therapeutics, Inc.13G5.57%4,086,181Feb 17, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 17, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠